Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

TSX falls by most in 13 months as hawkish Fed, new variant weigh

11/30/2021 | 04:32pm EST

(Add details throughout; updates prices to close)

* TSX ends down 489.01 points, or 2.3%, at 20,659.99

* U.S. oil prices settle 5.4% lower

* Energy declines 2.9%; financials end 2.8% lower

* Toronto market loses 1.8% in November

TORONTO, Nov 30 (Reuters) - Canada's main stock index on Tuesday tumbled to its lowest level in nearly seven weeks, pressured by hawkish comments from Federal Reserve Chair Jerome Powell and worries that existing vaccines may not hold up against the COVID-19 Omicron variant.

The Toronto Stock Exchange's S&P/TSX composite index ended down 489.01 points, or 2.3%, at 20,659.99, its biggest decline since October 2020 and its lowest closing level since Oct. 13. For the month, it lost 1.8%.

"Canada is basically getting caught up in a general pullback in equity markets around the world," said Colin Cieszynski, chief market strategist at SIA Wealth Management.

Wall Street's main indexes fell after Powell signaled that the U.S. central bank would consider speeding up its withdrawal of bond purchases as inflation risks increase, piling pressure onto a market already nervous about the variant.

The CEO of drugmaker Moderna warned that COVID-19 vaccines are unlikely to be as effective against the variant.

U.S. crude oil futures settled 5.4% lower at $66.18 a barrel, while the TSX's energy sector lost 2.9%.

The heavily weighted financials group ended 2.8% lower even as Bank of Nova Scotia kicked off Canadian banks' fourth-quarter results reporting with better-than-expected profits driven by lower provisions.

Technology declined 2.1% and industrials were down 2.2%.

Domestic economic data was encouraging, showing the economy growing an annualized rate of 5.4% in the third quarter, but gained little traction with stock market investors.

"Q3 is quite a ways back in the rearview mirror ... the market is focusing on other things now," Cieszynski said. (Reporting by Fergal Smith; Additional reporting by Susan Mathew and Anisha Sircar in Bengaluru; Editing by Sandra Maler)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -1.63% 171.43 Delayed Quote.-31.46%
S&P 500 1.31% 4592.19 Delayed Quote.-4.90%
All news about MODERNA, INC.
06:49aEMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
06:47aEMA : Assessment of whether vaccination can cause capillary leak syndrome (is ongoing for ..
01/19Prior COVID infection more protective than vaccination during Delta surge, U.S. study f..
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
01/18US Stocks Slump as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on Financials
01/18US Stocks Start Week Lower as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on ..
01/18Morgan Stanley Adjusts Moderna Price Target to $315 From $313, Maintains Equal Weight R..
01/18Equities Slump Midday After Treasury Yields Touch Two-Year High, Goldman's Earnings Mis..
01/18MIDDAY REPORT : US Stocks Slump After Treasury Yields Touch Two-Year High; Goldman's Earni..
01/18EU regulator finds mRNA COVID-19 shots safe during pregnancy
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 520 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,59x
Yield 2021 -
Capitalization 70 577 M 70 577 M -
EV / Sales 2021 3,47x
EV / Sales 2022 2,36x
Nbr of Employees 1 300
Free-Float 90,5%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 19
Last Close Price 174,07 $
Average target price 273,19 $
Spread / Average Target 56,9%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
CELLTRION, INC.-15.66%19 573